Endomorphin-1/2 showed cAMP-biased signaling while dynorphin-B showed G-protein-biased signaling at the mu opioid receptor, consistent across three cell lines.
Natural bias existsthe body's own opioid peptides already show biased signaling, suggesting safer pain drugs could mimic specific natural patterns
What the researchers found
Endomorphin-1 and endomorphin-2 showed a bias toward cAMP signaling at the mu opioid receptor (MOR), while dynorphin-B showed a bias toward G-protein (35S-GTPgammaS) signaling. This pattern was consistent across multiple cell lines expressing human MOR.
The researchers investigated whether RGS-4 (a G-protein regulator) or adenylyl cyclase 6 (AC6) might explain the endomorphin bias. However, neither an RGS-4 inhibitor nor AC6 knockdown significantly changed the bias profile, ruling out these specific mechanisms.
Biased agonism at opioid receptors is important because different signaling pathways may lead to different physiological effects. Pain relief, euphoria, respiratory depression, and constipation are thought to be mediated by different downstream pathways.
Why it matters
Understanding biased agonism at opioid receptors could help develop pain medications that relieve pain without causing dangerous side effects like respiratory depression. If the body's own peptides already show signaling bias, that bias may be harnessable for drug design.
The finding that endogenous peptides have built-in bias challenges the simple view that all opioid agonists act the same way at the same receptor.
The numbers in context
Endomorphin-1/2 cAMP-biased; dynorphin-B G-protein-biased; consistent across 3 cell lines; RGS-4 and AC6 not responsible
How the study worked
Researchers used three cell lines (CHO, N2a, SH-SY5Y) expressing human MOR to measure signaling bias between 35S-GTPgammaS binding (G-protein activation) and cAMP assays. They used an RGS-4 selective inhibitor and siRNA knockdown of AC6 in N2a cells to probe mechanisms.
Who was studied
CHO, N2a, SH-SY5Y cells expressing human MOR
What this study cannot tell us
This was entirely a cell-based study using overexpression systems, which may not fully reflect signaling in neurons. The functional consequences of the observed bias in terms of pain, reward, or side effects were not tested.
The mechanisms underlying the bias remain unclear after ruling out RGS-4 and AC6.
How to read the evidence
Moderate evidence from in vitro studies across three cell lines. Signaling bias is clearly demonstrated but functional consequences need in vivo confirmation.
When this study was published
Published in 2020. Biased opioid agonism is a major area of research for safer pain drugs.
The bigger picture
If nature's own opioid peptides show biased signaling, this provides clues for designing safer pain medications. Drugs that mimic the specific signaling pattern associated with analgesia — while avoiding the pattern linked to respiratory depression — could provide pain relief without the deadly side effect.
Questions still open
- Which signaling bias correlates with pain relief vs respiratory depression?
- Could endomorphin analogs provide analgesia with fewer side effects?
- Does signaling bias change in chronic pain states?
Common questions
What is biased signaling?
Could this lead to safer painkillers?
Read the original research
The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor.
Pharmacological reports : PR, 72(2), 465-471
Citation
LaVigne, Justin; Keresztes, Attila; Chiem, Daniel; Streicher, John M. (2020). The endomorphin-1/2 and dynorphin-B peptides display biased agonism at the mu opioid receptor.. Pharmacological reports : PR, 72(2), 465-471. https://doi.org/10.1007/s43440-020-00061-x